Vasculitis & polymyalgia rheumatica
The OMERACT giant cell arteritis ultrasonography score: a potential predictive outcome for assessing the risk of relapse during follow-up
Authors' conclusion
The absence of OGUS improvement during follow-up in GCA may be used to assess the probability of relapse and the absence of remission at 6 months.
Study context
- Population
- GCA patients referred to two US GCA fast-track clinics over 2 years, US evaluation at baseline, 3 and 6 months
- Participants
- 76 patients
- Exposure
- OMERACT GCA US Score (OGUS) change in patients with vs without relapse at 6 months
- Relapsen = 19
- Outcome
- OGUS change after treatment and probability of relapse
- Follow-up
- 6 months
Methodological detailsmulticentre, two US GCA fast-track clinics
- Multicentre
- Two US GCA fast-track clinics
Main finding
As reported in the abstract
Mean 0-6-month OGUS improvement
- Mean 0-6-month OGUS improvement lower in patients who relapsed (−0.1 to 0.16)
- P = 0.037
Observational data: associations, not effects.
Further findings
OGUS change in non-relapsing patients
- Baseline to 6 months: 1.18 to 0.99
- P = 0.004
- 3 to 6 months: 1.08 to 0.99
- P = 0.04
OGUS change in relapsing patients
- At 3 months: 1.17 to 1.17
- P = 0.736
- At 6 months: 1.17 to 1.21
- P = 0.343
- No significant changes
Mean 0-6-month OGUS improvement (decrease), remission vs no remission at 6 months
- Greater in patients who achieved remission (0.28 to −0.07)
- P = 0.001
- EULAR remission at 6 months in 32 (43.8%) patients
SMD in OGUS
- Baseline to 3 months
- −0.25
- 3 to 6 months
- −0.38
Relapse at 6 months
- Relapse
- 19 (26%)
- Minor relapse
- 14 (19.1%)
- Major relapse
- 5 (6.8%)
Original publication
The OMERACT giant cell arteritis ultrasonography score: a potential predictive outcome for assessing the risk of relapse during follow-up. Rheumatology (Oxford). Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →